抗程序性细胞死亡蛋白 1/抗程序性细胞死亡配体 1 药物治疗的癌症患者疲劳风险：系统评价和荟萃分析。
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis.
机构信息
Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100, Macerata, Italy.
Azienda Ospedaliera dell'Alto Adige, Bressanone/Brixen Hospital, Via Dante, 51, 39042, Italy.
出版信息
Immunotherapy. 2018 Nov;10(15):1303-1313. doi: 10.2217/imt-2018-0067.
AIM
We aimed to assess the incidence and relative risk (RR) of fatigue in cancer patients treated with anti programmed cell death-1 (PD-1) and anti programmed cell death ligand-1 (PD-L1) agents.
PATIENTS & METHODS: Eligible studies were selected according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Incidence, RR and 95% CIs were calculated using random or fixed-effects models.
RESULTS
Thirty-eight studies were included in this analysis, with a total of 11,719 patients. The incidences were 23.4 and 2.1% for all- and high-grade fatigue, respectively. The highest incidence of high-grade fatigue was reported by the combination of nivolumab and ipilimumab. Overall RR of high-grade fatigue with anti-PD-1/PD-L1 compared with chemotherapy or targeted therapy was 0.48.
CONCLUSION
Treatment with anti-PD-1/PD-L1 agents correlates with lower incidence and RR of fatigue compared with standard therapies.
目的
评估接受抗程序性细胞死亡蛋白-1（PD-1）和抗程序性细胞死亡配体-1（PD-L1）药物治疗的癌症患者发生疲劳的发生率和相对风险（RR）。
患者与方法
根据系统评价和荟萃分析的首选报告项目（PRISMA）声明，选择了符合条件的研究。使用随机或固定效应模型计算了发生率、RR 和 95%置信区间（CI）。
结果
这项分析纳入了 38 项研究，共计 11719 例患者。总疲劳和高等级疲劳的发生率分别为 23.4%和 2.1%。纳武利尤单抗联合伊匹单抗的报告高等级疲劳发生率最高。与化疗或靶向治疗相比，抗 PD-1/PD-L1 药物治疗的高等级疲劳的总体 RR 为 0.48。
结论
与标准疗法相比，抗 PD-1/PD-L1 药物治疗与疲劳发生率和 RR 降低相关。
Zotero 插件